FDA Submits Proposed Collection of Information for Review Under Paperwork Reduction Act

Summary

The Food and Drug Administration (FDA) has submitted a proposed collection of information to the Office of Management and Budget (OMB) for review and clearance, as required by the Paperwork Reduction Act of 1995, in order to draft guidance on postmarketing adverse event reporting for medical products and dietary supplements during an influenza pandemic.